POST Online Media Lite Edition


iOnctura appoints Joanna Horobin as chair

Christian Fernsby |
Geneva, Switzerland - iOnctura, a clinical stage biopharmaceutical company, announced that it has appointed Joanna Horobin as non-executive chair to the iOnctura board.

Article continues below

Dr. Horobin joined the pharma industry, first at Beecham Pharmaceuticals (now GSK), in 1982.

Whilst at Rhone Poulenc Rorer (now Sanofi), in France and USA, she shifted to cancer drug development which has been her major career focus.

She led a joint venture between Rhone Poulenc and Chugai to develop and launch Chugai's gCSF product Granocyte in Europe and, as VP Oncology, launched Rhone Poulenc Rorer as a major player in oncology with the global launch of Taxotere.

Dr. Horobin gained her medical qualifications from the University of Manchester Medical School in the United Kingdom.


Glencore appoints David Wormsley as director
MoonLake Immunotherapeutics appoints chairman and director
Glencore appoints Kalidas Madhavpeddi as chairman
MoonLake Immunotherapeutics appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO
WSSCC names Dominic O'Neill as executive director